Seres Therapeutics, Inc. (NASDAQ:MCRB) is set to announce third quarter earning results on Monday 9th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, MCRB to report 3Q20 loss of $ 0.25 per share.
For the full year, analysts anticipate top line of $ 29.03 million, while looking forward to loss of $ 0.96 per share bottom line.
Previous Quarter Performance
Seres Therapeutics, Inc. announced loss for the second quarter of $ 0.28 per share, from the revenue of $ 6.04 million. Street analysts expected Seres Therapeutics, Inc. to report loss of $ 0.26 per share on revenue of $ 9.54 million for the second quarter. The bottom line results missed street analysts by $ 0.02 or 7.69 percent, at the same time, top line results fell short of analysts by $ 3.5 million or 36.69 percent.
Stock Performance
On Friday, shares of Seres Therapeutics, Inc. has traded high as $ 36.00 and has cracked $ 33.76 on the downward trend, reaching $ 34.59 with volume of 773.80 thousand shares.
According to the previous trading day, closing price of $ 34.59, representing a 1,297.62 % increase from the 52 week low of $ 2.52 and a 2.17 % decrease over the 52 week high of $ 36.00.
The company has a market capital of $ 3.09 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 21st September 2020, maintained by Canaccord Genuity at Buy rating, with $ 42.00 target price.
- On 18th September 2020, downgraded by Chardan Capital to Neutral from Buy rating.
Conference Call
Seres Therapeutics, Inc. will be hosting a conference call at 8:30 AM eastern time on 9th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.serestherapeutics.com
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The companys advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study in patients with active mild-to-moderate ulcerative colitis; and SER-401, which is in Phase Ib study in metastatic melanoma to augment the efficacy of anti-PD-1 immunotherapy.
